Mounjaro vs Saxenda
Side-by-side comparison of Mounjaro (tirzepatide (T2D injection)) and Saxenda (liraglutide (daily injection)) across efficacy, food restrictions, monthly cost, and Medicare Bridge coverage.
Mounjaro
Based on the data below, Mounjaro wins on lower cash price ($1069/mo vs $1349/mo). Your situation may differ — try the personalized matcher on the homepage or compute your real out-of-pocket with the cost calculator on each medication's detail page.
Mounjaro
tirzepatide (T2D injection) · Eli Lilly and Company
| Field | Mounjaro | Saxenda |
|---|---|---|
| Route | injection · weekly | injection · daily |
| Avg weight loss | 12–16% | 5–8% |
| Food restriction | No food restriction | No food restriction |
| Cash from | $1069/mo | $1349/mo |
| Savings card | — | — |
| Medicare Bridge | Tier 4 | Tier 4 |
| A1c reduction | −2.4% | — |
| FDA approved | 2022-05 | 2014-12 |
- RouteMounjaroinjection · weeklySaxendainjection · daily
- Avg weight lossMounjaro12–16%Saxenda5–8%
- Food restrictionMounjaroNo food restrictionSaxendaNo food restriction
- Cash fromMounjaro$1069/moSaxenda$1349/mo
- Savings cardMounjaro—Saxenda—
- Medicare BridgeMounjaroTier 4SaxendaTier 4
- A1c reductionMounjaro−2.4%Saxenda—
- FDA approvedMounjaro2022-05Saxenda2014-12
Pick Mounjaro if…
- You can't reliably do a fasting window before meds
- Cash pay matters more than peak weight loss ($1069/mo cheaper)
- You want the higher peak efficacy (16% vs 8%)
Pick Saxenda if…
- You can't reliably do a fasting window before meds
Not sure which fits?
The 30-second matcher on the homepage scores every 2026 GLP-1 against your goals + preferences and recommends the best fit.